# Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

> **NCT02720094** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 4570 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir Oral Tablet
- **DRUG:** TDF/FTC tablets
- **DRUG:** Placebo for TDF/FTC tablets
- **DRUG:** Placebo for cabotegravir oral tablet
- **DRUG:** CAB LA
- **DRUG:** Placebo for CAB LA

## Key facts

- **NCT ID:** NCT02720094
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-19
- **Primary completion:** 2020-05-14
- **Final completion:** 2025-03-31
- **Target enrollment:** 4570 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720094, "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02720094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*